Differential effects of histamine, vasoactive intestinal polypeptide, prostaglandin E2 and somatostatin on cyclic AMP-dependent protein kinase activation in gastric glands isolated from the guinea pig fundus and antrum.

Mangeat P, Gespach C, Marchis-Mouren G, Rosselin G

Regulatory peptides1 Feb 1982Cited by 17 (Europe PMC)

PMID6121356DOI10.1016/0167-0115(82)90092-1PepBankPUB-06121356

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In isolated guinea pig gastric glands from fundus and antrum, VIP stimulated cyclic AMP-dependent protein kinase activity.
In plain wordsIn lab tests on guinea pig stomach glands, VIP switched on a cell-signalling enzyme (protein kinase).
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseCyclic AMP-dependent protein kinase activity
Study
guinea pign: not reported in source
isolated gastric glands (fundus and antrum)
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Histamine, vasoactive intestinal polypeptide (VIP), secretin and prostaglandin E2 (PGE2) stimulate cyclic AMP-dependent protein kinase activity in gastric glands isolated from the guinea pig fundus and antrum.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects are observed in the absence of any cyclic AMP phosphodiesterase inhibitor and maximal stimulation of the protein kinases occurs within 0.5 min of incubation at 20 degrees C.
Report a problemFND-0612135601
02LabEx vivo tissueActivity measurement
In isolated guinea pig gastric glands, VIP was equally potent in antrum and fundus, with identical activation constants of 2.5 x 10(-9) M.
In plain wordsIn lab tests on guinea pig stomach glands, VIP worked equally well in the antrum and the fundus.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP potency in antrum versus fundus
Study
guinea pign: not reported in source
isolated gastric glands (fundus and antrum)
Comparator
Fundic glands versus antral glands
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Measurements
activation constant Ka
2.5 x 10(-9) M
antrum and fundus
Source sentences
Summary
As shown by dose-response studies, VIP is equally potent in the antrum as in the fundus (identical values of the activation constant are found in both types of gland, Ka = 2.5 . 10(-9) M); a similar situation occurs for PGE2 action (but with Ka = 2.0 .
1 context sentence(design, population, supporting numbers)
Summary · context
The effects are observed in the absence of any cyclic AMP phosphodiesterase inhibitor and maximal stimulation of the protein kinases occurs within 0.5 min of incubation at 20 degrees C.
Report a problemFND-0612135602
03LabEx vivo tissueActivity measurement
In isolated guinea pig gastric glands, secretin raised protein kinase activity ratio with a potency 1000 times lower than VIP.
In plain wordsIn lab tests on guinea pig stomach glands, secretin worked 1000 times more weakly than VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablePotency of secretin relative to VIP
Study
guinea pign: not reported in source
isolated gastric glands (fundus and antrum)
Comparator
Secretin
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Measurements
relative potency of secretin versus VIP
1000 fold lower
gastric glands
Source sentences
Summary
Secretin also increases the protein kinase activity ratio but with a 1000 times lower potency than VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects are observed in the absence of any cyclic AMP phosphodiesterase inhibitor and maximal stimulation of the protein kinases occurs within 0.5 min of incubation at 20 degrees C.
Report a problemFND-0612135603
04LabEx vivo tissueActivity measurement
In isolated guinea pig fundic glands, 10(-7) M VIP raised protein kinase activity to 1.4 times the basal value.
In plain wordsIn lab tests on guinea pig stomach glands, VIP raised the activity of a signalling enzyme to 1.4 times baseline.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseProtein kinase activity in fundic glands at 10(-7) M VIP
Study
guinea pign: not reported in source
isolated gastric glands (fundus and antrum)
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
10(-7) MAs given in this study (guinea pig).
Measurements
protein kinase activity vs basal
1.4 fold
fundic glands, VIP 10(-7) M
Source sentences
Summary
In fundic glands, histamine (10(-3) M) is the activator of by far the greatest efficacy (increasing protein kinase activity at 4 times of the basal value) as compared with the effect obtained with 10(-6) M PGE2 (2.7 times) and 10(-7) M VIP (1.4 times).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects are observed in the absence of any cyclic AMP phosphodiesterase inhibitor and maximal stimulation of the protein kinases occurs within 0.5 min of incubation at 20 degrees C.
Report a problemFND-0612135604
05LabEx vivo tissueActivity measurement
In isolated guinea pig antral glands, VIP had greater efficacy (2.3 times) than histamine (2.1 times) in activating protein kinase.
In plain wordsIn lab tests on guinea pig stomach antrum glands, VIP activated the signalling enzyme slightly more than histamine did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseProtein kinase activation efficacy in antral glands versus histamine
Study
guinea pign: not reported in source
isolated gastric glands (fundus and antrum)
Comparator
Histamine
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Measurements
protein kinase activation
2.3 fold
antral glands, VIP
protein kinase activation
2.1 fold
antral glands, histamine
Source sentences
Summary
In contrast, VIP has greater efficacy (2.3 times) than histamine (2.1 times) in antral glands, whereas PGE2 is equally active in the two parts of the gastric mucosa.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects are observed in the absence of any cyclic AMP phosphodiesterase inhibitor and maximal stimulation of the protein kinases occurs within 0.5 min of incubation at 20 degrees C.
Report a problemFND-0612135605

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement
In isolated guinea pig gastric glands, somatostatin at 10(-6) M had no effect on VIP-induced protein kinase activation (VIP was the stimulus).
In plain wordsIn lab tests on guinea pig stomach glands, somatostatin did not change the enzyme activation caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeSomatostatin effect on VIP-induced protein kinase activation
Study
guinea pign: not reported in source
isolated gastric glands (fundus and antrum)
Outcome group
Receptor activity and mechanism · Gastrointestinal
Source sentences
Summary
whereas it has no effect on VIP- and PGE2-induced activation.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects are observed in the absence of any cyclic AMP phosphodiesterase inhibitor and maximal stimulation of the protein kinases occurs within 0.5 min of incubation at 20 degrees C.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0612135606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.